fda warning letters glp-1 compounded september 2025 Issues 30 to Telehealth Firms Over Misleading Marketing FDA Issues Warning Letters to

Dose escalation in the phase 3 trial is designed to reduce the incidence of gastrointestinal adverse events when switching to monthly dosing

The lifestyle intervention, compared to usual care, was also not associated with significant reductions in any of the secondary outcomes

Kaplan said it's important to remember these symptoms are uncommon once you're on a stable dose

Researchers familiar with expired semaglutide safety concerns understand that the same principles apply to expired tirzepatide

There were also apparent reductions in triglycerides by a mean of -48 mg/dl, cholesterol by a mean of -8 mg/dl, and non-high-density lipoprotein by a mean of -7 mg/dl